Skip to content Skip to footer
Subscribe Now
Viewpoints_Jane Chung
VIEWPOINTS

Expanding ADC Therapy: Jane Chung from Sutro Biopharma in an Engaging Conversation with PharmaShots

Shots:   Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF   Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta   Sutro is now enrolling patients for the…
July 24, 2024

Read more

Insights+ EMA Marketing Authorization of New Drugs in June 2024
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in June 2024

Shots:   The EMA granted Positive Opinion to 4 Biologics and 3 New Chemical Entities in June 2024, leading to treatments for patients and advances in the healthcare industry  The major highlighted drugs were Merck’s Winrevair to treat Pulmonary Arterial Hypertension (PAH) and Roche’s PiaSky for Paroxysmal Nocturnal Haemoglobinuria (PNH)  PharmaShots has compiled a list of 5 drugs that…
July 23, 2024

Read more

Know Your Investor: Invus (July’24 Edition)
INSIGHTS+

Know Your Investor: Invus (July’24 Edition)

Shots:    Backed with an evergreen investment strategy, Invus makes investments across several company stages ranging from early growth to turnarounds   In 2023, Invus participated in 6 investment rounds in around 29 companies focusing on biopharma, manufacturing & services, and devices   For a curated report on a specific investor or venture capital, reach out to us…
July 17, 2024

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots:   Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M   KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation  …
July 15, 2024

Read more

PharmaShots Magazine - July 2024 Edition
MAGAZINE

PharmaShots Magazine – July 2024 Edition

In June, PharmaShots was busy covering the heavy influx of life science updates. Our most-read Top 20 reports covered Nutraceutical and Innovative Digital Therapeutics companies. For the Disease of the Month report, we covered Fabry Disease. The Know Your Investor report featured a condensed report on Google Ventures.  Like every Month, we published reports on Biosimilars, Designations, FDAand EMA approvals.  In August, PharmaShots will…
July 10, 2024

Read more

ThoughtSpot_Saurabh Chaubey5
THOUGHTSPOT

4 Biopharma Trends to Watch out in 2024

Shots:  2023 had been a great year for the biopharma industry despite several imposed restrictions from the IRA and inflation  With several swaying factors impacting the biopharma industry, including social, economic, regulatory and others, some of the noteworthy trends that emerged in 2024 and are shaping the ways biopharma companies operate  The article explores four key…
July 9, 2024

Read more

CXO TALKS

CXO Talks: David A. Dodd, Chairman President and CEO of GeoVax Labs Inc. in a riveting conversation with PharmaShots

With great zeal, PharmaShots began an Exclusive Video Interview series for C-suites. An innovative idea to bring thought leaders of the industry, our Exclusive Video Interview offering is a noble initiative by PharmaShots to capture the developments of leading companies. As a part of offering, PharmaShots will be publishing exclusive video interviews every second Monday…
July 8, 2024

Read more

Insights+ Key Biosimilars Events of June 2024
INSIGHTS+

Insights+ Key Biosimilars Events of June 2024

Shots:    Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency     Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients     The major highlights were NMPA’s approval of Simcere Zaiming’s Enlituo for Treating metastatic colorectal…
July 4, 2024

Read more

Viewpoints_Andrew Menzies-Gow
VIEWPOINTS

AstraZeneca at ATS’24: Andrew Menzies-Gow from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots:  AstraZeneca presented 59 abstracts, including 12 late-breaking posters at the American Thoracic Society, focussing on the unmet needs in COPD, EGPA, and other chronic respiratory diseases  Today, at PharmaShots, we have Andrew Menzies-Gow, sharing insights from the MANDARA study that evaluated Fasenra (benralizumab) for EGPA, a rare debilitating condition  Andrew stresses reducing the use…
July 3, 2024

Read more

Load more